Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Itraconazole on GLPG3667 PK in Healthy Subjects
NCT05272683Phase 1Completed
- Sponsor
- Galapagos NV
- Start
- Feb 2022
- Primary completion
- Apr 2022
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cadefrecitinib in psoriasis, dermatomyositis (DM) and systemic lupus erythematosus (SLE), sponsored by Galapagos NV. Primary endpoints: Maximum observed plasma concentration at Day 12 and Area under the plasma concentration-time curve from time zero to infinity at Day 12. Started Feb 2022; status: completed.
02
Drugs
cadefrecitinib
03
Conditions
psoriasisdermatomyositis (DM)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT05272683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05272683.